HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare
HeartSciences (NASDAQ: HSCS) has been selected to demonstrate its MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium in September 2024. The Innovation Value Institute chose the technology as one that can radically transform healthcare. This selection follows HeartSciences' recent presentation at IVI's International Digital Health Summer School 2024.
Professor Martin Curley of Maynooth University emphasized the need for technologies delivering 10X improvements in healthcare, shifting towards preventative and proactive care. He highlighted MyoVista wavECG as a prime example, noting its benefits in frontline healthcare for early disease identification.
Andrew Simpson, CEO of HeartSciences, expressed honor at the recognition and anticipation for the upcoming demonstration. He also mentioned recent successes, including increased support from key opinion leaders and establishing relationships in the UK and Ireland, underscoring the commercial potential of their AI-ECG products.
HeartSciences (NASDAQ: HSCS) è stata selezionata per dimostrare il suo MyoVista® wavECG™ al Simposio sulla Salute Digitale dell'Assemblea Generale delle Nazioni Unite nel settembre 2024. L'Innovation Value Institute ha scelto questa tecnologia, ritenuta in grado di trasformare radicalmente l'assistenza sanitaria. Questa selezione segue la recente presentazione di HeartSciences all'International Digital Health Summer School 2024 di IVI.
Il Professor Martin Curley dell'Università di Maynooth ha sottolineato la necessità di tecnologie che offrano miglioramenti dieci volte superiori nell'assistenza sanitaria, spostandosi verso una cura preventiva e proattiva. Ha evidenziato MyoVista wavECG come un esempio importante, notando i suoi vantaggi nell'assistenza sanitaria diretta per l'identificazione precoce delle malattie.
Andrew Simpson, CEO di HeartSciences, ha espresso il suo onore per il riconoscimento e l'attesa per la prossima dimostrazione. Ha inoltre menzionato i recenti successi, tra cui un maggiore supporto da parte di leader di opinione chiave e l'instaurazione di relazioni nel Regno Unito e in Irlanda, sottolineando il potenziale commerciale dei loro prodotti AI-ECG.
HeartSciences (NASDAQ: HSCS) ha sido seleccionada para demostrar su MyoVista® wavECG™ en el Simposio de Salud Digital de la Asamblea General de las Naciones Unidas en septiembre de 2024. El Innovation Value Institute eligió esta tecnología como una que puede transformar radicalmente la atención médica. Esta selección sigue a la reciente presentación de HeartSciences en la International Digital Health Summer School 2024 de IVI.
El Profesor Martin Curley de la Universidad de Maynooth enfatizó la necesidad de tecnologías que ofrezcan mejoras de 10 veces en la atención médica, cambiando hacia una atención preventiva y proactiva. Destacó MyoVista wavECG como un ejemplo primordial, señalando sus beneficios en la atención médica de primera línea para la identificación temprana de enfermedades.
Andrew Simpson, CEO de HeartSciences, expresó su honor por el reconocimiento y su anticipación por la próxima demostración. También mencionó los éxitos recientes, incluyendo un mayor apoyo de líderes de opinión clave y el establecimiento de relaciones en el Reino Unido e Irlanda, subrayando el potencial comercial de sus productos de AI-ECG.
HeartSciences (NASDAQ: HSCS)는 2024년 9월 유엔 총회 디지털 헬스 심포지엄에서 MyoVista® wavECG™를 시연하도록 선정되었습니다. 혁신 가치 연구소(IVI)는 이 기술이 의료를 근본적으로 변화시킬 수 있는 기술로 선정했습니다. 이 선정은 HeartSciences가 IVI의 국제 디지털 헬스 여름학교 2024에서 최근 발표한 것에 이어 이루어졌습니다.
메이누스 대학교의 마틴 커리 교수는 10배의 개선을 제공하는 기술의 필요성을 강조하며 예방적이고 능동적인 치료로의 전환이 필요하다고 언급했습니다. 그는 조기 질병 식별을 위한 최전선 의료에서 MyoVista wavECG의 이점을 강조했습니다.
HeartSciences의 CEO인 앤드류 심슨은 이 인정을 받게 되어 영광스럽고 다가오는 시연에 대한 기대감을 표했습니다. 그는 또한 주요 의견 리더들의 지원 증가와 영국 및 아일랜드에서의 관계 구축을 포함한 최근의 성공 사례를 언급하며, 그들의 AI-ECG 제품의 상업적 잠재력을 강조했습니다.
HeartSciences (NASDAQ: HSCS) a été sélectionnée pour présenter son MyoVista® wavECG™ lors du Symposium sur la Santé Numérique de l'Assemblée Générale des Nations Unies en septembre 2024. L'Innovation Value Institute a choisi cette technologie comme étant capable de transformer radicalement les soins de santé. Cette sélection fait suite à la récente présentation de HeartSciences lors de l'International Digital Health Summer School 2024 de l'IVI.
Le professeur Martin Curley de l'Université de Maynooth a souligné la nécessité de technologies offrant des améliorations 10 fois supérieures dans le secteur des soins de santé, en se dirigeant vers des soins préventifs et proactifs. Il a mis en avant MyoVista wavECG comme un exemple clé, en notant ses avantages dans les soins de santé de première ligne pour l'identification précoce des maladies.
Andrew Simpson, PDG de HeartSciences, a exprimé son honneur d'être reconnu et son impatience pour la prochaine démonstration. Il a également mentionné les récents succès, y compris un soutien accru de la part de leaders d'opinion et l'établissement de relations au Royaume-Uni et en Irlande, soulignant le potentiel commercial de leurs produits d'AI-ECG.
HeartSciences (NASDAQ: HSCS) wurde ausgewählt, um ihr MyoVista® wavECG™ auf dem Digital Health Symposium der Generalversammlung der Vereinten Nationen im September 2024 vorzuführen. Das Innovation Value Institute erklärte die Technologie als eine, die die Gesundheitsversorgung revolutionär verändern kann. Diese Auswahl folgt auf die kürzliche Präsentation von HeartSciences an der International Digital Health Summer School 2024 des IVI.
Professor Martin Curley von der Maynooth University betonte die Notwendigkeit von Technologien, die 10-fache Verbesserungen im Gesundheitswesen bieten, und einen Wechsel hin zu präventiver und proaktiver Versorgung. Er hob MyoVista wavECG als herausragendes Beispiel hervor und wies auf dessen Vorteile in der ersten Gesundheitsversorgung zur frühzeitigen Krankheitsidentifikation hin.
Andrew Simpson, CEO von HeartSciences, äußerte seine Ehre über die Anerkennung und seine Vorfreude auf die bevorstehende Vorführung. Er erwähnte auch kürzliche Erfolge, darunter eine stärkere Unterstützung von führenden Meinungsbildnern und den Aufbau von Beziehungen im Vereinigten Königreich und in Irland, womit er das kommerzielle Potenzial ihrer AI-ECG-Produkte unterstrich.
- Selection to demonstrate MyoVista® wavECG™ at the UN General Assembly Digital Health Symposium
- Recognition as a technology that can radically transform healthcare
- Increasing support from key opinion leaders
- Establishing relationships in the UK and Ireland for their technology
- None.
Southlake, TX, July 25, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that the MyoVista® wavECGTM has been selected by the Innovation Value Institute as a technology which can drive the radical transformation of healthcare and has been invited to demonstrate and discuss the MyoVista wavECG at the 4th Digital Health Symposium at the United Nations General Assembly to be held in New York, USA in September 2024.
Founded in 2006, the Innovation Value Institute (IVI) is a multidisciplinary research institute focused on digital transformation and technology adoption based in Maynooth University, Ireland. The selection follows HeartSciences recent presentation and demonstration of the MyoVista wavECG at IVI’s International Digital Health Summer School 2024 focused on AI in Health and Data and Electronic Health Records which brought together international representatives from health systems, governments and industry.
Professor Martin Curley, Professor of Innovation at Maynooth University, said, “Healthcare challenges globally cannot be fixed with marginal gains. They need technologies and solutions that deliver 10X improvements and shift away from emergency and elective treatment into preventative and proactive care. The MyoVista wavECG is a prime example of such a technology and we have observed firsthand the benefits of its use in frontline healthcare to identify disease early.”
Andrew Simpson, CEO of HeartSciences, said, “We are honored that the MyoVista wavECG has been recognized as a technology with the potential to radically transform healthcare and look forward to our demonstration at the United Nations General Assembly Digital Health Symposium in September. This builds on our recent successes that include increasing support from key opinion leaders and establishing relationships in the UK and Ireland for our technology. It also evidences the enormous commercial opportunity for our AI-ECG products.”
About HeartSciences
Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and is developing AI-ECG solutions to be made available on either a hardware agnostic cloud-based platform or its proprietary MyoVista® wavECG™ device, to help identify cardiovascular disease in any care setting worldwide in a manner to best suit different care providers. HeartSciences' first product candidate for FDA clearance, the MyoVista® wavECG™, or the MyoVista®, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista® also provides conventional ECG information in the same test.
For more information, please visit: https://heartsciences.com/. X: @HeartSciences
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences' beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences' Annual Report on Form 10-K for the fiscal year ended April 30, 2023, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 18, 2023, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2024, filed with the SEC on March 14, 2024 and in HeartSciences' other filings with the SEC at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
Contacts:
HeartSciences
Gene Gephart
+1-682-244-2578 (US)
info@heartsciences.com
Investors
Gilmartin Group
Vivian Cervantes
investorrelations@heartsciences.com
FAQ
What is HeartSciences' stock symbol?
When will HeartSciences demonstrate MyoVista® wavECG™ at the UN General Assembly?
Who selected HeartSciences' technology for the UN General Assembly demonstration?
What recent successes has HeartSciences (HSCS) reported?
